Navigation Links
Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Date:9/11/2007

LAUSANNE, Switzerland, September 11 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today announced that it received current Good Manufacturing Practices (cGMP) certification from Swissmedic for the chemical, physical and biochemical quality control work conducted at its laboratory in Gland, Switzerland. At the same time, certification of the Lausanne site was extended for the manufacture of medicinal products, including the packaging of investigational medicinal products. This achievement gives Debiopharm the alternative to handle its analytical development, formulation and quality control activities in-house when necessary.

"This certification is very important for the optimal development of our products," said Kamel Besseghir, CEO of Debiopharm. "Our laboratory in Gland is the internal quality reference for our outsourced activities in CMC (chemistry, manufacturing and control). We now have more flexibility and reactivity in CMC development, analysis and supply of drug products for clinical studies, one of our major strengths."

Debiopharm also has a cGMP development and production facility in Martigny, Switzerland, which has been inspected by the United States Food and Drug Administration (FDA) and Swissmedic. The company can produce pilot batches of cGMP drug products for feasibility studies, clinical trial supplies and commercial scale manufacturing.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, dr
'/>"/>

SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... ("CTI") (Nasdaq and MTA: CTIC) announced today that it has been ... posted by Russell Investments on June 29, 2009 on ... and global equity indexes on an annual basis. , ... largest U.S. stocks as of the last trading day of May, ...
... Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing ... added to the Russell 3000 and Russell 2000 Indexes effective ... 2009. The Russell family of U.S. indexes is reconstituted annually ... investable U.S. equity market. , , The Russell 3000 ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, today announced that ... part of the annual reconstitution of the Russell indexes, ... "Investors recognize the Russell 3000 as an established benchmark ...
Cached Biology Technology:Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 2Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 3BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes 2Micromet Added to Russell 3000 Index 2Micromet Added to Russell 3000 Index 3Micromet Added to Russell 3000 Index 4
(Date:7/9/2014)... fungal pathogens pose a greater threat to biodiversity ... of amphibians, bats, corals, bees and snakes. New ... in the prestigious journal Nature reveals ... to a deadly chytrid fungus implicated in global ... important because it is the basis of vaccination ...
(Date:7/9/2014)... Guelph scientist that involved fitting bumblebees with tiny ... neonicotinoid pesticide hampers bees, ability to forage for ... professor in Guelph,s School of Environmental Sciences, and ... July 9 in the British Ecological Society,s journal ... how long-term pesticide exposure affects individual bees, day-to-day ...
(Date:7/9/2014)... fever but often can be defeated with antibiotics and ... beat. Now, scientists have built a new weapon against such ... the journal ACS Applied Materials & Interfaces , their ... of them than medicine alone. , David Leong, Jianping Xie ... wait, undetectable in the human body or in places that ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Bee foraging chronically impaired by pesticide exposure: Study 2
... why a tuberculosis vaccine is not as effective for some ... not work as well for some as they do for ... issue of the Journal of Leukocyte Biology ( ... common environmental bacterium found in soil and water, can decrease ...
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... New Rochelle, NY, November 30, 2010Access to quality reproductive ... aspect of a woman,s human rights, freedom, equity, and ... on Global Women,s Reproductive Health in the current issue ... by Mary Ann Liebert, Inc., explores the compelling medical, ...
Cached Biology News:Blame the environment: Why vaccines may be ineffective for some people 2Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Ensuring the rights of women worldwide to reproductive health care 2
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Recombinant Human Erythropoietin (Tissue Culture Grade)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Human PDGF R beta MAb (Clone # PR7212)...
Biology Products: